CYCN Stock Analysis: Buy, Sell, or Hold?
CYCN - Cyclerion Therapeutics, Inc. Common Stock
$5.84
4.29 (276.77%)
▲
5d:
+260.49%
30d:
+332.59%
90d:
+394.92%
WAIT
LOW Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: Mar 31, 2026
0d
Get Alerted When CYCN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: CYCN is 125.5% above fair value ($2.59). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: CYCN is 125.5% above fair value ($2.59). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: CYCN is currently trading at $5.84, which is considered extended relative to its 30-day fair value range of $0.67 to $2.59.
Technical Outlook: Technically, CYCN is showing sideways momentum. Immediate support is located at $1.40, while resistance sits at $8.48. The stock is showing strong short-term momentum, up 276.8% recently.
Market Sentiment: CYCN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.00 (+416.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CYCN is showing sideways momentum. Immediate support is located at $1.40, while resistance sits at $8.48. The stock is showing strong short-term momentum, up 276.8% recently.
Market Sentiment: CYCN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.00 (+416.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$0.67 -
$2.59
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+125.5% above fair value)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+276.8%)
- BULLISH: Trading 416.1% below Wall St target ($8.00)
- WARNING: Recommendation downgraded due to 125.5% overvaluation
Fair Price Analysis
30-Day Fair Range
$0.67 -
$2.59
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$1.40
Resistance Level
$8.48
Current Trend
Sideways
Technical data as of
Apr 1, 2026
Fundamental Context
Wall Street Target
$8.00
(+416.1%)
Revenue Growth (YoY)
351.0%
Profit Margin
-77.0%
Share & Embed Analysis
Last updated: April 01, 2026 1:48 PM ET
Data refreshes hourly during market hours. Next update: 2:48 PM
Data refreshes hourly during market hours. Next update: 2:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CYCN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 66 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$43 | 65 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 62 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 48 HOLD |
